Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to propranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.
Abstract
Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to propranolol therapy can improve hepatic venous pressure gradient (HVPG) response. Methods: Sixty-four cirrhosis patients were randomly assigned to propranolol monotherapy (n=48) versus rifaximin and propranolol combination therapy (n=16). Baseline and post-treatment HVPG values, BT-related markers (lipopolysaccharide [LPS], LPS-binding protein [LBP], interleukin-6 [IL-6], and tumor necrosis factor α [TNF-α]), serological data, and adverse event data were collected. HVPG response rate was the primary endpoint. Results: Combination therapy was associated with better HVPG response rates than monotherapy (56.2% vs 87.5%, p=0.034). In combination therapy, posttreatment BT-related markers were significantly decreased (LPS, p=0.005; LBP, p=0.005; IL-6, p=0.005; TNF-α, p=0.047). Conclusions: Rifaximin combination therapy showed an additive effect in improving PHT compared to propranolol monotherapy. These pilot data suggest that the addition of rifaximin to NSBBs could be a good therapeutic option for overcoming the limited effectiveness of NSBBs.
참고문헌 (37)
- La Mura V, "Cirrhosis and portal hypertension: the importance of risk stratification, the role of hepatic venous pressure gradient measurement", World J Hepatol, 7, pp.688~695 (2015)
- 엄영우, "Mesenchymal stem cell therapy for liver fibrosis", The Korean Journal of Internal Medicine, 30(5), pp.580~589 (2015), 대한내과학회[DOI]
- Kapoor A, "Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding", Gastrointest Endosc Clin N Am, 25, pp.491~507 (2015)
- Groszmann RJ, "Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med, 353, pp.2254~2261 (2005)
- Tripathi D, "Beta-blockers in portal hypertension: new developments and controversies", Liver Int, 34, pp.655~667 (2014)
- 김가은, "Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis", Journal of Korean Medical Science, 30(10), pp.1405~1415 (2015), 대한의학회
- Giannelli V, "Beta-blockers in liver cirrhosis", Ann Gastroenterol, 27, pp.20~26 (2014)
- Reiberger T, "Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis", J Hepatol, 58, pp.911~921 (2013)
- 김재현, "Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension", Clinical and Molecular Hepatology, 20(4), pp.376~383 (2014), 대한간학회
- Koutsounas I, "Markers of bacterial translocation in end-stage liver disease", World J Hepatol, 7, pp.2264~2273 (2015)
- Bellot P, "Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications", Liver Int, 33, pp.31~39 (2013)
- Koo HL, "Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases", Curr Opin Gastroenterol, 26, pp.17~25 (2010)
- Ponziani FR, "Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications", World J Gastroenterol, 21, pp.12322~12333 (2015)
- Bajaj JS, "Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis", Aliment Pharmacol Ther, 41, pp.39~45 (2015)
- Bass NM, "Rifaximin treatment in hepatic encephalopathy", N Engl J Med, 362, pp.1071~1081 (2010)
- La Mura V, "Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window", World J Gastroenterol, 21, pp.2265~2268 (2015)
- Kim MY, "Hemodynamic alterations in cirrhosis and portal hypertension", Korean J Hepatol, 16, pp.347~352 (2010)
- Garcia-Tsao G, "Portal hypertension and variceal bleeding: unresolved issues. Summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver single-topic conference", Hepatology, 47, pp.1764~1772 (2008)
- Lebrec D, "Methods to evaluate portal hypertension", Gastroenterol Clin North Am, 21, pp.41~59 (1992)
- Kim MY, "Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis", Eur J Gastroenterol Hepatol, 21, pp.1241~1246 (2009)
- 제동모, "The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleedi", Clinical and Molecular Hepatology, 20(3), pp.283~290 (2014), 대한간학회[DOI]
- 김가은, "Assessment for Risk of Bias in Systematic Reviews and Meta-Analyses in the Field of Hepatology", Gut and Liver, 9(6), pp.701~706 (2015), 거트앤리버 발행위원회
- Suk KT, "Hepatic venous pressure gradient: clinical use in chronic liver disease.", Clin Mol Hepatol, 20, pp.6~14 (2014)
- Guarner C, "Bacterial translocation and its consequences in patients with cirrhosis", Eur J Gastroenterol Hepatol, 17, pp.27~31 (2005)
- Fukui H, "Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia", World J Hepatol, 7, pp.425~442 (2015)
- Giannelli V, "Microbiota and the gutliver axis: bacterial translocation, inflammation and infection in cirrhosis", World J Gastroenterol, 20, pp.16795~16810 (2014)
- Rasaratnam B, "The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial", Ann Intern Med, 139, pp.186~193 (2003)
- Fernández J, "Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study", Hepatology, 55, pp.1551~1561 (2012)
- Tandon P, "High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center", Clin Gastroenterol Hepatol, 10, pp.1291~1298 (2012)
- DuPont HL, "Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases", Aliment Pharmacol Ther, 43(Suppl 1), pp.1~2 (2016)
- Maharshi S, "Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed", Gut, 64, pp.1341~1342 (2015)
- Vlachogiannakos J, "Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis", Aliment Pharmacol Ther, 29, pp.992~999 (2009)
- Kimer N, "Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial", Hepatology, 65, pp.592~603 (2017)
- Thalheimer U, "How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers", Gastroenterology, 133, pp.2029~2036 (2007)
- Mookerjee RP, "Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure", J Hepatol, 64, pp.574~582 (2016)
- Pimentel M, "The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial", Ann Intern Med, 145, pp.557~563 (2006)
- Leevy CB, "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy", Dig Dis Sci, 52, pp.737~741 (2007)